Mirae Asset Global Investments’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-7,322
| Closed | -$528K | – | 1712 |
|
|
2025
Q4 | $528K | Sell |
7,322
-14,403
| -66% | -$930K | ﹤0.01% | 983 |
|
|
2025
Q3 | $947K | Buy |
21,725
+5,409
| +33% | +$219K | ﹤0.01% | 889 |
|
|
2025
Q2 | $463K | Buy |
16,316
+746
| +5% | +$22.2K | ﹤0.01% | 954 |
|
|
2025
Q1 | $492K | Buy |
15,570
+11,594
| +292% | +$361K | ﹤0.01% | 930 |
|
|
2024
Q4 | $120K | Sell |
3,976
-260
| -6% | -$10.9K | ﹤0.01% | 1122 |
|
|
2024
Q3 | $179K | Buy |
4,236
+1,381
| +48% | +$59.9K | ﹤0.01% | 1102 |
|
|
2024
Q2 | $116K | Sell |
2,855
-34,607
| -92% | -$993K | ﹤0.01% | 1122 |
|
|
2024
Q1 | $798K | Sell |
37,462
-128,557
| -77% | -$2.01M | ﹤0.01% | 1656 |
|
|
2023
Q4 | $1.5M | Buy |
166,019
+124,633
| +301% | +$833K | ﹤0.01% | 1398 |
|
|
2023
Q3 | $264K | Sell |
41,386
-7,981
| -16% | -$68.8K | ﹤0.01% | 2190 |
|
|
2023
Q2 | $547K | Buy |
49,367
+6,904
| +16% | +$86.6K | ﹤0.01% | 1903 |
|
|
2023
Q1 | $652K | Buy |
42,463
+17,241
| +68% | +$379K | ﹤0.01% | 1799 |
|
|
2022
Q4 | $560K | Buy |
25,222
+3,407
| +16% | +$50.8K | ﹤0.01% | 1829 |
|
|
2022
Q3 | $356K | Buy |
21,815
+9,729
| +80% | +$186K | ﹤0.01% | 2074 |
|
|
2022
Q2 | $175K | Buy |
+12,086
| New | +$180K | ﹤0.01% | 2184 |
|
Other funds holding RNAM
Mirae Asset Global Investments's RNAM Position: Q1 2026 in Review
Mirae Asset Global Investments sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 7,322 shares — an estimated $528K sold.
Mirae Asset Global Investments first reported a position in RNAM in Q2 2022 and held it in 15 quarters. The position peaked at $1.5M in Q4 2023. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Mirae Asset Global Investments reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Mirae Asset Global Investments sold 7,322 Avidity Biosciences shares in Q1 2026, an estimated $528K.
- Mirae Asset Global Investments first reported a position in Avidity Biosciences in Q2 2022 and held it in 15 quarters.
- Mirae Asset Global Investments's Avidity Biosciences position peaked at $1.5M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Mirae Asset Global Investments's 13F filing for Q1 2026, filed 4 May 2026.